Court of appeal convicts former employees - Peptonic Medical AB Imposed with Corporate Fine as a Result

Peptonic Medical AB (publ) ("Peptonic" or the "Company") announces that the Court of Appeal has overturned the District Court’s acquittal in the insider trading case involving events from the spring of 2019 and individuals from the Company’s former management. The Court of Appeal has found the former employees guilty of aggravated insider trading, and consequently, the Company being imposed with a corporate fine of SEK 500,000.

The ruling pertains to an investigation into aggravated insider trading related to a financing arrangement in the spring of 2019, in which the convicted former employees were involved. After an investigation by the Swedish Economic Crime Authority (EBM), several individuals from the Company’s former management were prosecuted. In June 2023, the District Court acquitted all defendants and rejected the claim for a corporate fine. EBM appealed the decision, and the Court of Appeal has now overturned the District Court’s ruling.

Peptonic Medical AB will review the ruling and assess potential next steps.

This disclosure contains information that PEPTONIC Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on March 14, 2025, at 17:00 CET.

For further information, please contact:
Anna Linton, CEO, Peptonic Medical AB                                                                                                             
Email: anna.linton@peptonicmedical.se                                                                                                                                         
Phone: +46 70-244 92 07

About Peptonic Medical AB                                                                                                        
PEPTONIC medical AB (publ) is a pioneering Swedish Medical Device company specializing in the development and sale of clinically proven self-care products for women’s intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic’s growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.

The Company is headquartered in Stockholm, Sweden, and operates a subsidiary, Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.